Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 11369 - 11376 of 12140 results

Wage and Hour Considerations and Inclement Weather: In the Wake of Hurricane Sandy

November 6, 2012| Blog| Viewpoint

New York Employers May Not Seek to Prevent Their Employees From Voting or Attempt to Improperly Influence Their Votes

November 5, 2012| Blog| Viewpoint

Commercial Landlords Seek Share of Tenants' Online Sales

November 4, 2012| News

2013 Medicare Physician Fee Schedule: Issues of Interest to Independent Laboratories

November 2, 2012| Blog| Viewpoint

The FTC Fires Back Against Wyndham

November 2, 2012| Blog| Viewpoint

Google and Rosetta Stone Settle AdWords Trademark Infringement Suit

October 31, 2012| Blog| Viewpoint

Section 409A Document Correction Relief: Take the Final Bite of the Apple before December 31st

October 30, 2012| Blog| Viewpoint

Second Circuit Applies the Filed Rate Doctrine to Electricity Rates Set by Market-Based Auctions

October 29, 2012| Blog| Viewpoint

News & Press Releases

Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber

September 15, 2025

Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering

September 12, 2025

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement

September 12, 2025

Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.

View all News and Press Releases